fda update on semaglutide 🚨 Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like and tirzepatide, signaling a major shift in how these FDA Approves Oral Semaglutide as

Mechanisms accounting for development of overweight/obesity in T1D patients include: iatrogenic peripheral hyperinsulinemia related to intensive insulin therapy (due to peripheral insulin administration, such as subcutaneous insulin administration) [178], physical inactivity and increased caloric intake [45] (for example, due to the fear of hypoglycemia or due to the treatment of frequent episodes of hypoglycemia) [44,179], unhealthy food consumption, T1D-specific biopsychosocial burden, exposure to an obesogenic environment, socioeconomic and cultural factors [45], binge eating disorder and disordered eating behaviors [180], genetic susceptibility, epigenetics, hormonal alterations other than insulin deficiency (e.g., alterations involving the secretion of amylin, glucagon, leptin, ghrelin and other gastrointestinal hormones), dysregulation of biologic mechanisms regulating appetite and satiety, sociodemographic disparities, gut microbiota dysbiosis, adipose tissue dysfunction, lipotoxicity, and glucotoxicity [45,181]

You can check the latest NICE guidance on weight management for updates

Curious about GLP-1 weight loss

Curcumin, the active compound in turmeric, has been studied for its role in supporting this balance

regulators flagged severe and sometimes fatal pancreatitis cases in 2007-2008 for the earlier GLP-1 drug Byetta (exenatide) and advised clinicians to stop therapy if patients develop persistent severe abdominal pain radiating to the back In the United States, nearly 2,000 GLP-1 lawsuitsprimarily alleging severe gastrointestinal injuries (gastroparesis, bowel obstruction, related complications) after Ozempic, Wegovy, Mounjaro, Trulicity, and other agentsare centralized in federal Multidistrict Litigation (MDL No